Table 5.

The current trend in treating the high-grade glioma patients with CAR-T-based therapy.

No.	Intervention	Cancer type	Clinical trial phase	(estimated) study start date	The status	Clinicaltrials.gov Identifier
1	B7-H3 CAR-T + Temozolomide	Recurrent/refectory glioblastoma	Phase I	1-Jun-20	Recruiting	NCT04385173
2	NKG2D CAR-T	Recurrent glioblastoma	Not applicable	1-Sep-21	Not yet recruiting	NCT04717999
3	B7-H3 CAR-T + Temozolomide	Recurrent/refectory glioblastoma	Phase I/II	1-May-22	Recruiting	NCT04077866
4	GD2 CAR-T + Fludarabine + Cyclophosphamide	Glioma of spinal cord/glioma of brainstem	Phase I	4-Jun-20	Recruiting	NCT04196413
5	CD147-CAR-T	Recurrent CD147 positive glioblastoma	Early phase I	30-May-19	Recruiting	NCT04045847
6	IL13Rα2-CAR-T + Nivolumab + Ipilimumab	Recurrent/refectory glioblastoma	Phase I	26-Sep-19	Recruiting	NCT04003649
7	CAR-T + Radiation + TCR-T + GM-CSF	High-grade glioma	Phase I	1-Apr-18	Recruiting	NCT03392545
8	CAR-T	Recurrent malignant glioma	Phase I	2-Mar-18	Recruiting	NCT03423992
9	IL13Rα2-CAR-T Cell	Leptomeningeal metastases of glioblastoma	Phase I	15-Feb-21	Recruiting	NCT04661384
10	B7-H3 CAR-T	Diffuse glioma	Phase I	11-Dec-19	Recruiting	NCT04185038
11	Fludarabine + Cyclophosphamide + C7R-GD2.CAR-T	High-grade glioma	Phase I	3-Feb-20	Recruiting	NCT04099797